Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2014—Health Canada approved Roche’s Cobas 4800 HPV Test for use as a first-line primary screening test for cervical cancer in women 25 and older. Roche also launched the fully automated CINtec Plus test to improve the detection and early intervention of precancerous cervical disease. The Health Canada–approved CINtec Plus cytology test helps identify women with high-grade precancerous cervical lesions who need immediate colposcopy.
July 2014—OpGen launched a molecular-based test that can identify patients at risk for harboring serious disease-causing, antibiotic-resistant microbes, the Acuitas MDRO Gene Test. The test uses DNA amplification and detection technology to detect as many as seven genes from one patient sample—genes associated with deadly bacteria, including carbapenem-resistant enterobacteriaceae containing KPC, NDM-1, and OXA-48 genes—within 24 hours.
July 2014—DiaSorin received FDA clearance for its Liaison N-Tact PTH Gen II immunoassay, intended for the quantitative determination of intact human parathyroid hormone in human serum and plasma samples. The kit contains 200 tests and has an open-kit shelf life of 8 weeks, meeting the needs of small- and large-volume laboratories. It also has low cross-reactivity to the 7-84 and other inactive fragments, supporting conservative patient management.
July 2014—Myriad Genetics presented new data from a clinical validation study of Prolaris at the American Urological Association annual meeting in May. A key finding was that the Prolaris molecular diagnostic test accurately differentiated newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower-risk disease. The goal was to validate the Prolaris test score in 761 conservatively managed prostate cancer patients diagnosed by needle biopsy.
July 2014—Horizon Discovery entered into a nonexclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene-editing system. Under the terms of the agreement, Horizon has rights to use the technology commercially for applications including development of research tools and reagents.
July 2014—Vermillion launched Aspira Labs, which will specialize in using a biomarker-based diagnostic algorithm to inform clinical decision-making and advance personalized treatment plans in the management of gynecologic cancers. The lab, based in Austin, Tex., will also serve as an education and resource hub for health care professionals and women facing surgery for ovarian masses that are potentially cancerous and other related gynecologic conditions.
July 2014—Meridian Life Science now has a sampling kit with HIV-1 p24 reagents for developing sensitive and specific HIV-1 p24 sandwich immunoassays. The kit includes a 0.25-mg vial of capture antibody, MAb to HIV-1 p24; a 0.25-mg vial of detection antibody, MAb to HIV-1 p24; and a 0.25-mg vial of recombinant HIV-1 p24 antigen (strain HxB2) expressed in Pichia pastoris
July 2014—Qiagen’s artus C. difficile QS-RGQ MDx Kit received FDA clearance, and its QIAsymphony RGQ MDx system was granted 510(k) regulatory clearance by the FDA. In addition, the artus VanR QS-RGQ MDx Kit for detection of vancomycin-resistant bacteria, available in Europe, is expected to be submitted to the FDA this year. The artus MRSA QS-RGQ MDx Kit for methicillin-resistant Staphylococcus aureus is expected to be launched in Europe this year and submitted to the FDA in the third quarter of 2014. Test kits for diagnosis of group B streptococcus and herpes simplex virus (HSV 1/2) are in the advanced stages of development.
July 2014—Leica Microsystems opened an Experience Lab in its Tokyo headquarters. The laboratory is dedicated to product demonstrations of Leica microscope systems and workshops. Additionally, it serves as a showroom for microscope users who wish to get to know the instruments and accessories, such as cameras, illumination, and software. Users can bring their own samples to observe with the systems and can take advantage of a sample preparation service for industrial samples to be observed and analyzed on site.
July 2014—BioView announced that the FDA cleared for marketing its automated scanning microscope and image analysis system, the Duet, to qualitatively detect rearrangements involving the ALK gene via fluorescence in situ hybridization in formalin-fixed, paraffin-embedded non-small cell lung cancer tissue specimens, probed with the Abbott Vysis ALK Break Apart FISH Probe Kit.
